Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af JNJ-80948543 i kombination med andre CD3 T-celle-engagers hos deltagere med recidiverende/refraktær B-celle non-Hodgkin-lymfom (R/R B-celle NHL)

2. november 2026 opdateret af: Janssen Research & Development, LLC

Et fase 1b-studie af JNJ-80948543 i kombination med andre CD3 T-celle-engagers (TCE'er) hos deltagere med recidiverende/refraktære B-celle non-Hodgkin lymfoide (R/R B-celle NHL) maligniteter

The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

19

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Concord, Australien, 2139
        • Concord Hospital
      • Fitzroy, Australien, 3065
        • St Vincents Hospital Melbourne
      • North Ryde, Australien, 2109
        • Macquarie University Hospital
      • Leicester, Det Forenede Kongerige, Le1 5ww
        • University Hospitals Of Leicester Nhs Trust
      • Barcelona, Spanien, 08036
        • Hosp. Clinic de Barcelona
      • Barcelona, Spanien, 08035
        • Hosp Univ Vall D Hebron
      • L'Hospitalet de Llobregat, Spanien, 08908
        • Inst. Cat. Doncologia-H Duran I Reynals
      • Madrid, Spanien, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanien, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologic documentation of diffuse large B-cell lymphoma (DLBCL), including high-grade B-cell lymphoma and DLBCL arising from indolent lymphoma. All participants must have received at least 2 prior lines of therapy
  • Participants must have measurable disease as defined by the appropriate disease response criteria
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Hematologic laboratory parameters must meet the required criterias and the values must be without a transfusion or growth factors for at least 7 days prior to the first dose of study drug
  • Participants of childbearing potential must have a negative highly sensitive serum pregnancy test (beta (β)-human chorionic gonadotropin) at screening and within 24 hours before the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study

Exclusion Criteria:

  • Known active central nervous system involvement (CNS) or leptomeningeal involvement
  • Prior solid-organ transplantation
  • Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
  • Clinically significant pulmonary compromise defined as the need for supplemental oxygen to maintain adequate oxygenation
  • Evidence of clinically significant and/or symptomatic infection (viral, bacterial, or fungal) at the time of study drug initiation. Anti-microbial treatment for infection must be discontinued at least 7 days before the first dose of study drug

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: JNJ-80948543

Participants will receive JNJ-80948543 in combination with JNJ-75348780 to determine the recommended phase 2 regimen (RP2R) in Part 1 (Dose escalation). JNJ-80948543 will be dosed in an escalation manner in combination with fixed doses of JNJ-75348780. In Part 2 (Dose expansion) participants will receive RP2R of JNJ-80948543 as determined in Part 1 in combination with JNJ-75348780.

JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.

JNJ-75348780 will be administered as SC injection.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants with Dose-limiting Toxicity (DLT)
Tidsramme: Up to 1 year and 10 months

Number of participants with DLT will be reported. DLTs are defined as any of the treatment-related toxicities: any toxicity that would require discontinuation of treatment; Fatal toxicity; Non-hematologic toxicity (Grade 3 toxicity or higher with exceptions); and Hematologic Toxicity (Grade 4 neutrophil count decrease; Grade 4 febrile neutropenia; Grade 3 febrile neutropenia that does not recover with best supportive care within 7 days; Grade 4 platelet count decrease for >=7 days or Grade >3 with Grade >=2 bleeding; Grade 4 anemia).

Up to 1 year and 10 months
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 1 year and 10 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 1 year and 10 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serum Concentration of JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months

Serum Concentration for JNJ-80948543 and JNJ-75348780 will be reported.

Up to 1 year and 10 months
Area Under the Curve (AUCtau) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months

AUC tau is defined as area under the serum concentration-time curve during a dosing interval for JNJ-80948543 and JNJ-75348780.

Up to 1 year and 10 months
Maximum Serum Concentration (Cmax) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months

Cmax for JNJ-80948543 and JNJ-75348780 will be reported.

Up to 1 year and 10 months
Time to Reach Cmax (Tmax) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months

Tmax is the time to reach maximum observed serum concentration for JNJ-80948543 and JNJ-75348780.

Up to 1 year and 10 months
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months

Number of participants with presence of anti-drug antibodies of JNJ-80948543 and JNJ-75348780 will be assessed.

Up to 1 year and 10 months
Overall Response Rate (ORR)
Tidsramme: Up to 1 year and 10 months

ORR is defined as the percentage of participants who have a best response of partial response (PR) or better as assessed by the investigator based on standard response criteria.

Up to 1 year and 10 months
Complete Response Rate (CRR)
Tidsramme: Up to 1 year and 10 months

CR is defined as the percentage of participants who achieve a best response of CR as assessed by the investigator based on standard response criteria.

Up to 1 year and 10 months
Duration of Response (DoR)
Tidsramme: Up to 1 year and 10 months

DOR is defined as the time from the first efficacy evaluation at which the participant meet all criteria for a response of PR or better to the date of first documented evidence of progressive disease or death as assessed by the investigator based on standard response criteria.

Up to 1 year and 10 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2024

Primær færdiggørelse (Faktiske)

19. januar 2026

Studieafslutning (Anslået)

31. marts 2027

Datoer for studieregistrering

Først indsendt

25. oktober 2024

Først indsendt, der opfyldte QC-kriterier

25. oktober 2024

Først opslået (Faktiske)

28. oktober 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 80948543LYM1002
  • 80948543LYM1002 (Anden identifikator: Janssen Research & Development, LLC)
  • 2024-514176-41-00 (Registry Identifier: EUCT number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .